Arvinas
ARVN
Market cap $571M

8.30 USD

-9.26

52.73%

At close Mar 11, 4:00 PM EDT

After hours

8.32

+0.02

0.24%

1 day

-52.73%

5 days

-50.48%

1 month

-53.05%

3 months

-63.18%

6 months

-66.65%

Year to date

-56.06%

1 year

-81.76%

5 years

-81.16%

10 years

-48.29%

About: Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Employees: 430

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 7,363 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

315% more call options, than puts

Call options by funds: $30.8M | Put options by funds: $7.41M

57% more repeat investments, than reductions

Existing positions increased: 80 | Existing positions reduced: 51

40% more funds holding in top 10

Funds holding in top 10: 5 [Q3] → 7 (+2) [Q4]

4.51% more ownership

Funds ownership: 106.93% [Q3] → 111.44% (+4.51%) [Q4]

4% less funds holding

Funds holding: 205 [Q3] → 196 (-9) [Q4]

18% less first-time investments, than exits

New positions opened: 28 | Existing positions closed: 34

19% less capital invested

Capital invested by funds: $1.81B [Q3] → $1.47B (-$338M) [Q4]

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$19

129%

upside

Avg. target

$52

532%

upside

High target

$82

888%

upside

7 analyst ratings

6 positive

86%

1 neutral

14%

0 negative

0%

HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 113 / 355 met price target	876%upside $81	Buy Reiterated	11 Mar 2025
Citigroup Yigal Nochomovitz 19% 1-year accuracy 8 / 42 met price target	129%upside $19	Neutral Maintained	7 Mar 2025
Oppenheimer Matthew Biegler 11% 1-year accuracy 3 / 28 met price target	442%upside $45	Outperform Maintained	12 Feb 2025
BMO Capital Etzer Darout 29% 1-year accuracy 10 / 35 met price target	888%upside $82	Outperform Reiterated	12 Feb 2025
Guggenheim Michael Schmidt 41% 1-year accuracy 12 / 29 met price target	587%upside $57	Buy Reiterated	12 Feb 2025

See Analyst Rankings

Financial journalist opinion

Based on 12 articles about ARVN published over the past 30 days

Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial

Arvinas, Inc. ARVN and Pfizer Inc. PFE released topline results from the Phase 3 VERITAC-2 trial evaluating vepdegestrant monotherapy versus fulvestrant in adult patients with advanced or metastatic breast cancer.

Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial

Investors Business Daily

Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug

Arvinas stock lost half its value Tuesday after the biotech company reported mixed results from its Pfizer-partnered breast cancer drug. The post Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug appeared first on Investor's Business Daily.

Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug

Arvinas-Pfizer's breast cancer treatment meets main goal in late-stage study

Pfizer and Arvinas' experimental drug to treat a type of breast cancer met the main goal in a late-stage study, the companies said on Tuesday.

Arvinas-Pfizer's breast cancer treatment meets main goal in late-stage study

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

– VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful improvement in progression-free survival – – Vepdegestrant is the first PROTAC degrader to demonstrate clinical benefit in a Phase 3 trial – NEW HAVEN, Conn. and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer whose disease progressed following prior treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors and endocrine therapy.

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

Arvinas to Participate in Upcoming Investor Conferences

NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three upcoming investor conferences:

Arvinas to Participate in Upcoming Investor Conferences

Zacks Investment Research

Wall Street Analysts Predict a 228.87% Upside in Arvinas (ARVN): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 228.9% in Arvinas (ARVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 228.87% Upside in Arvinas (ARVN): Here's What You Should Know

Zacks Investment Research

All You Need to Know About Arvinas (ARVN) Rating Upgrade to Buy

Arvinas (ARVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Arvinas (ARVN) Rating Upgrade to Buy

Zacks Investment Research

How Much Upside is Left in Arvinas (ARVN)? Wall Street Analysts Think 235.09%

The mean of analysts' price targets for Arvinas (ARVN) points to a 235.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in Arvinas (ARVN)? Wall Street Analysts Think 235.09%

These Analysts Revise Their Forecasts On Arvinas After Q4 Results

Arvinas, Inc. ARVN reported worse-than-expected fourth-quarter sales results on Tuesday.

These Analysts Revise Their Forecasts On Arvinas After Q4 Results

Arvinas, Inc. (ARVN) Q4 2024 Earnings Call Transcript

Arvinas, Inc. (NASDAQ:ARVN ) Q4 2024 Earnings Conference Call February 11, 2025 8:00 AM ET Company Participants Jeff Boyle - Vice President of Investor Relations John Houston - President and Chief Executive Officer Noah Berkowitz - Chief Medical Officer Angela Cacace - Chief Scientific Officer Andrew Saik - Chief Financial Officer Conference Call Participants Derek Archila - Wells Fargo & Company Jonathan Miller - Evercore ISI Li Watsek - Cantor Fitzgerald Akash Tewari - Jefferies Group LLC Tazeen Ahmad - Bank of America Srikripa Devarakonda - Truist Securities Jeet Mukherjee - BTIG, LLC Bradley Canino - Stifel Financial Corp. Sudan Loganathan - Stephens Inc. Edward Tenthoff - Piper Sandler Companies Ellie Merle - UBS Group AG Paul Choi - Guggenheim Securities Michael Schmidt - Guggenheim Partners, LLC Operator Good day, and thank you for standing by. Welcome to the Arvinas Fourth Quarter 2024 Earnings Conference Call.

Arvinas, Inc. (ARVN) Q4 2024 Earnings Call Transcript

See News Rankings

Charts implemented using Lightweight Charts™